Block Listing Return and Total Voting Rights

RNS Number : 7751L

Allergy Therapeutics PLC

15 January 2021

 

Allergy Therapeutics plc

("Allergy Therapeutics", "ATL" or the "Group")

Block Listing Return and Total Voting Rights

Block Listing Return

Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, makes the following update on its block listings, pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies.  

Name of applicant:		ALLERGY THERAPEUTICS PLC
Name of scheme:		Allergy Therapeutics plc 2013 Long Term Incentive Plan
Period of return:	From:	2 July 2020	To:	15 January 2021
Number and class of share(s) (amount of stock / debt securities) originally listed and the date of admission:		10,000,000 ordinary shares of 0.1p each in the Company admitted to trading on 24 November 2017
Balance of unallotted securities under scheme(s) from previous return:		6,831,964
Plus:   The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		-
Less:   Number of securities issued/allotted under scheme(s) during period:		3,506,360
Equals:   Balance under scheme(s) not yet issued/allotted at end of period:		3,325,604

Name of contact:	Sara Goldsbrough
Telephone number of contact:	[phone]

Total Voting Rights

Allergy Therapeutics also announces that  pursuant to its block admission facility, details of which were announced on 20 November 2017, it has recently issued 928,437 ordinary shares of 0.001 pence each ("Ordinary Shares") in satisfaction of the exercise of share options. The new Ordinary Shares rank pari passu with the Company's existing shares.

In accordance with DTR 5.6.1 of the Financial Conduct Authority's Disclosure Guidance and Transparency Rules, as at 15 January 2021, the Company has 640,792,164 Ordinary Shares in issue. There are no shares held in treasury. The total number of voting rights in the Company is therefore 640,792,164.

The above figure of 640,792,164 may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

For further information, please contact:

Allergy Therapeutics

[phone]

Manuel Llobet, Chief Executive Officer

Nick Wykeman, Chief Financial Officer

Panmure Gordon

[phone]

Freddy Crossley, Emma Earl, Corporate Finance

Rupert Dearden, Corporate Broking

Consilium Strategic Communications

[phone]

Mary-Jane Elliott / David Daley / Nicholas Brown / Olivia Manser

[e-mail]

Stern Investor Relations, Inc.

[phone]

Christina Tartaglia

[e-mail]

Notes for editors:

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Other adjuvant systems to boost performance of vaccines outside allergy are also in development.

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m² of state-of-the-art MHRA-approved manufacturing facilities and laboratories.  The Group, which has achieved double digit compound annual growth since formation, employs c.500 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com.

 

END

 

 

TVRFLFITLAISLIL